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CHAPTER ONE: THE PROBLEM  
 
Introduction/Background 
 
Fibromyalgia (FMS) is a complex, chronic condition involving persistent and widespread 
pain of unknown origin. FMS is sometimes mistaken as psychiatric in origin; however, 
the precise origin and cause of FMS is unknown (Klippel et al., 1998). Worldwide 
prevalence rates range from 0.18-12%, with 0.18% in the United Kingdom (UK) (Hughes 
et al., 2006), 2% in the United States (US) (Wolfe et al., 1997), and 12% in Spain 
(Carmona et al., 2001). In the UK, there is debate over the existence of FMS (Bohr, 
1995), and the reluctance of a general practitioner (GP) to diagnose conditions that are 
poorly defined (Hughes et al., 2006).  
 
Primary symptoms of FMS include generalized muscular pain, multiple tender points, 
sleep disruption and excessive fatigue. Additional symptoms include headaches, memory 
and concentration problems, dizziness, numbness/tingling, itching, fluid retention, 
abdominal cramps or pelvic pain and diarrhea (Hudson et al., 1992). Clearly, these 
symptoms may have an immense impact on daily life, limiting an individual’s 
functioning and emotional well-being. 
 
 
Statement of the Problem 
 
Many FMS symptoms mimic those of other diseases; therefore, diagnosis is difficult. 
Clinical diagnosis of FMS should be based on the American College of Rheumatology 
(ACR) criteria for FMS. The ACR has developed criteria for FMS that physicians can use 
in diagnosing the condition. According to ACR criteria, a person is considered to have 
FMS if he or she reports widespread pain in all 4 quadrants of the body and more than 3 
months of excessive tenderness in at least 11 of 18 specific tender point sites on the body 
(Burckhardt et al., 2005). 
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There are currently no laboratory tests available to diagnose FMS (National Horizon 
Scanning Centre, 2005). Even though the ACR criteria are widely accepted in the UK and 
there is a growing recognition of FMS as a distinct subgroup of chronic pain sufferers, 
(Fibromyalgia Association, 2004), a survey of occupational and physiotherapists in the 
UK found that a substantial proportion of therapists (30%) indicated that up to half of 
their patients, whom they considered to have FMS (based on the ACR criteria), are 
referred under other diagnostic labels. Therefore, different criteria may be used amongst 
physicians to diagnose FMS (Sim and Adams, 2003). 
 
The diagnostic and treatment challenges of FMS make it a costly condition to manage. 
Because many patients affected by FMS are of prime working age, the condition may 
place a substantial economic burden on both private and public health care systems. 
Previous US studies have estimated the direct medical costs of FMS using self-reported 
data from small, community-based samples (Wolfe et al., 1997; White et al., 1999) and 
employer-based administrative data (Robinson et al., 2003, 2004), however there are no 
similar studies in the UK.  
 
 
Purpose of the Study 
 
FMS is associated with significant societal and health care costs. Patients with FMS may 
repeatedly present to the general practitioner with various symptoms before a definitive 
diagnosis of FMS is made. As a result, general practitioners may be more likely to 
diagnose FMS in patients who frequently present with symptoms related to FMS, while 
patients who meet the diagnostic criteria but who rarely present at the practice may be 
missed (Ehrlich, 2003). The condition is of unknown etiology, and this, together with the 
lack of verifiable diagnostic criteria (i.e. lab tests), has led some to speculate that the 
disease does not or is at best a surrogate marker for underlying psychosocial problems. 
As such, the very process of diagnosing a patient with FMS may exacerbate symptoms 
and lead to increased dependence on health care providers (Ehrlich, 2003). This study 
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examined the diagnoses of FMS made in “real-life” clinical practice and recorded by 
general practitioners in a large primary care population in the UK. 
 
There were 8 US studies that evaluated the economic impact of FMS; however, only 1 
study characterized resource use among FMS patients and no study was found in the 
literature that evaluated the direct cost of FMS in the UK. Due to the gap in the literature 
on the impact of FMS in the UK, the primary objectives of this study were to characterize 
patterns of medical and pharmacy resource utilization and associated costs for patients 
with FMS and compared levels of resource utilization before and after the FMS 
diagnosis. The secondary objective was to describe the characteristics of the patient 
population in terms of its epidemiology, demographics, and comorbidities. This pre-post 
study was designed to determine if a diagnosis of FMS will have a significant impact on 
the medical and pharmacy resource utilization of this patient population.  
 
 
Rationale and Theoretical Frameworks  
 
The assumption that FMS impacts medical and pharmacy costs was based on several 
theoretical frameworks: definition of FMS, clinical presentation, diagnosis, and treatment 
guidelines. FMS was defined as the presence of widespread chronic pain (for > 3 months) 
and the presence of excess tenderness to manual palpation of at least 11 of 18 specific 
muscle-tendon sites obtained through a manual tender point examination. The ACR 
created the criteria for the diagnosis of FMS. The criteria are: a history of widespread 
pain (i.e., bilateral, above and below the waist, and axial pain) and the presence of 
excessive tenderness on applying pressure (digital palpation with approximately 4 kg of 
force) at 11 or more of the following 18 specific bilateral tender point sites: 
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Bilateral Tender Point Sites 
1. Occiput: bilateral, at the subocciptal muscle insertions 
2. Low cervical: bilateral at the anterior aspects of the intertransverse spaces at 
C5-C7 
3. Trapezius: bilateral, at the midpoint of the upper border 
4. Supraspinatus: bilateral, at origins, above the scapula spine near the medical 
border 
5. Second rib: bilateral, at the second costochondral junctions, just lateral to the 
junctions on upper surfaces 
6. Lateral epicondyle: bilateral, 2 cm distal to epicondyles 
7. Gluteal: bilateral, in upper outer quadrants of buttocks in anterior fold of 
muscle 
8. Greater trochanter: bilateral, posterior to the trochanteric prominence 
9. Knee: bilateral, at the medial fat pad proximal to joint line 
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Figure 1: Algorithm used for the Assessment of Patients with Widespread Pain     
 
Source: Burckhardt CS et al. Guideline for the management of FMS syndrome pain in adults and children. 
APS Clinical Practice Guidelines Series, No. 4. Glenview, IL: American Pain Society; 2005. 
 
 
The ACR definition for FMS is widely accepted in the UK and a mandatory medical 
terminology coding system is used in primary care settings. Once a patient has been 
diagnosed with a FMS, the GP codes the diagnosis electronically using a Read/Oxford 
Medical Information System codes N248.00, N239.00, 7339F for “Fibromyalgia” or 
N241200 for “Fibromyositis, not otherwise specified”. Each term of the Read code 
identifies a symptom, sign, or diagnosis. The Oxford Medical Information System 
(OXMIS) codes preceded Read codes and were used until the late 1990s. Read codes are 
based on codes in the International Classification of Diseases, 9th Revision (ICD-9) 
(Hughes et al., 2006).  
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The clinical features of FMS may include widespread pain with allodynia and 
hyperalgesia, persistent fatigue, feeling of weakness, sleep disturbances, morning 
stiffness, bowel and bladder irritability, mood disturbances, cognitive difficulties (e.g., 
memory, concentration), dyesthesia/paresthesia, chronic rhinitis, palpitations, 
auditory/vestibular/ocular complaints, regional pain (e.g., headache, atypical chest pain, 
pelvic pain, temporomandibular disorder, myofascial pain), and joint swelling (Hudson et 
al., 1992; Winfield et al., 1999; Geisser et al., 2003).  
 
Many FMS symptoms are also associated with such syndromes as chronic fatigue 
syndrome (CFS), migraine and tension-type headaches, irritable bowel syndrome, or 
depression (Hudson et al., 1992). People with CFS and FMS have a wide range of 
symptom fluctuations and disability (from exercise intolerance to bed-bound 
confinement) as well as high levels of psychiatric morbidity (Leslie et al., 2000). The 
primary symptom of CFS is fatigue whereas pain is the primary symptom for FMS 
(Fukuda et al., 1994). CFS was defined as at least six months of persistent debilitating 
fatigue not attributable to any identifiable medical condition and at least four secondary 
symptoms such as post-exertional malaise, neurocognitive difficulties, sleep disturbance, 
multiple joint pains, or flu-like symptoms (Fukuda et al., 1994). Diagnosis for both of 
these syndromes is based primarily on patient-reported symptoms. However, using factor 
analysis of symptoms, it appears that CFS and FMS can be distinguished (Robbins et al., 
1997). They also respond differently to the treatment interventions which may be another 
way to differentiate them. 
 
Since FMS cannot be cured, the goal of treatment is to relieve symptoms and restore 
normal function. The treatment should initially focus on verifying the diagnosis of FMS, 
validating the symptoms, and involving the patient in disease management. It is also 
important to identify comorbid conditions and take them into account when creating a 
treatment regimen. A FMS treatment regimen should incorporate both pharmacological 
and non-pharmacological treatments. The most important non-pharmacologic treatment is 
education. Patients need to be educated about the disease, treatment options, and pain 
management. Referral to physical therapy or cognitive-behavioural therapy may be 
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appropriate for patients with persistent symptoms. Exercise, both aerobic and muscle-
strengthening, is another non-pharmacologic treatment often prescribed to FMS patients 
(Burckhardt et al., 2005). 
 
FMS is a complex syndrome associated with significant impairment on quality of life and 
function and substantial financial cost. Although its cause is not well understood, it is 
clear that interdisciplinary approaches to its management are probably the most 
beneficial. Therefore, once the diagnosis is made, providers should aim to increase 
patients’ function and minimize their pain complaints. This can be accomplished through 
different non-pharmacological and pharmacological interventions.  
 
 
Delineation of the Research Problem 
 
Since FMS is so complex and no objective clinical markers exist to diagnose the 
condition, some practitioners may not recognize the syndrome or may view the condition 
as a psychiatric disorder or as simply not credible. As a result, patients are left feeling 
confused and frustrated and are often left to cope with symptoms and the related impact 
on their own. The majority of FMS patients have been found to reduce activities and 
spend at least one day in bed during a 2-week period because of health symptoms (Wolfe 
et al 1995). FMS patients in the US have self-reported disability rates between 6.3% and 
23% (Wolfe, 1996). In the study by Bernard et al. (2000), they found that 53% of their 
sample stated that they were no longer working after a diagnosis of FMS. Of these 
respondents, 57% stated that their exit from the workforce was a direct result of FMS.  
 
A 1993 study investigated the functional impact of FMS in a large number of UK 
patients. Seventy-two patients suffering from primary FMS syndrome were reviewed at a 
mean of 4 years following diagnosis. Levels of both anxiety and depression were high in 
most patients, as measured by the Hospital Anxiety and Depression Scale (HADS), but in 
general, patients had higher levels of anxiety than depression. Functional status, 
evaluated by the HADS and Steinbroker index, was impaired in many patients, evidenced 
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by 32% describing themselves as heavily dependent on disability and 50% had stopped 
working as a result of FMS. These results clearly showed that functional impairment still 
existed at a median of 4 years follow-up, and anxiety and depression were highly 
correlated with severity of FMS (Ledingham et al., 1993). 
 
FMS is also associated with a high level of health care costs. A US study (Robinson et 
al., 2004) found that FMS claimants had 2.6 times more medical claims than the average 
beneficiary. In addition, 45% of the FMS claimants had at least one claim for other 
diseases of the ‘musculoskeletal and connective tissue’ compared to 16% in the sample of 
average beneficiaries and were more likely to use prescription medications. 
Approximately 76% of FMS claimants were seen a least once by a GP over a years time 
period.  
 
 
Statement of Hypothesis 
 
The primary hypothesis of this study was that FMS patients will have an increase in 
medical and pharmacy resource utilization and direct medical costs during the 12 month 
period after diagnosis. A study by Hughes et al. (2006) investigated the impact of a 
diagnosis of FMS in clinical practice on health care resource use in the UK. The study 
suggested that total clinical visits to a GP in primary care were found to be considerably 
higher in the FMS cases compared with matched controls for at least 10 years prior to 
diagnosis and rose sharply from 3 years prior to diagnosis, to 2,500 visits per 100 person-
years. Overall rates of referrals were also significantly higher in FMS cases compared 
with controls and following FMS diagnosis, referral rates declined considerably. 
Referrals to rheumatologists dropped to near the control levels by 4 years following 
diagnosis.  
 
 
 
Importance of the Study 
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 The diagnostic and treatment challenges of FMS make it a costly condition to manage. 
Because many patients affected by FMS are of prime working age, the condition may 
place a substantial economic burden on both private and public health care systems. 
Previous US studies have estimated the direct medical costs of FMS using self-reported 
data from small, community-based samples (Wolfe et al., 1997; White et al., 1999) and 
employer-based administrative data (Robinson et al., 2003; 2004). In a 2006 UK study, 
researchers analyzed data from the General Practice Research Database (GPRD) and 
found that FMS patients had higher total clinical visits for at least 10 years prior to 
diagnosis compared to controls (Hughes et al., 2006).  
 
 
Definition of Terms 
 
Direct Medical Cost 
Direct medical cost will be defined as the paid amount associated with the FMS diagnosis 
during the study period. 
 
Direct Medical Visits 
Direct medical visits will be defined as the number of medical utilizations associated with 
the FMS diagnosis. 
 
Direct Pharmacy Cost  
Direct pharmacy cost will be defined as the drug cost associated with the FMS diagnosis 
during the study period. 
 
Discontinuation 
Discontinuation will be defined as having > 60 day gap between exhaustion of previous 
fill supply and the end of the follow-up period: (follow-up period end date)-(last 
prescription fill date + day’s supply) > 60 days. 
Length of Therapy 
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Length of therapy will be defined as: (last medication prescription fill date + days’ 
supply) - (first medication prescription fill date) 
 
 
Scope of the Study 
 
This study describes the characteristics of the FMS patient population in terms of its 
epidemiology, demographics, and comorbidities; characterized patterns of medical and 
pharmacy resource utilization and associated costs for patients with FMS; and compared 
levels of resource utilization among FMS patients 12 months before and 12 months after 
the initial diagnosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER TWO: REVIEW OF RELATED LITERATURE 
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 Overview 
 
FMS patients present with numerous symptoms including widespread pain with allodynia 
and hyperalgesia, persistent fatigue, feeling of weakness, sleep disturbances, morning 
stiffness, bowel and bladder irritability, mood disturbances, cognitive difficulties, 
dyesthesia/paresthesia, chronic rhinitis, palpitations, auditory/vestibular/ocular 
complaints, regional pain and joint swelling (Hudson et al. 1992; Winfield, 1999; Geisser 
et al. 2003). Clinical diagnosis is based on ACR criteria of FMS.  
 
The overall prevalence of FMS is 2.0% (between 1990 and 1995) in the United States. 
FMS is more prevalent in women than men (nearly 7-fold more common). The 
prevalence of FMS increases with age: for women from 2% in the age range 30-39 years 
to 7% in the age range of 70-79 years and for men 0.2% in the age range 30-39 years to 
1.2% in the age range of 70-79 years (Wolfe et al., 1996; Wolfe et al., 1999). 
 
Although ACR has clearly defined diagnosis criteria, in the United Kingdom (UK), there 
is still a debate over the classification of FMS as a physiological instead of a 
psychological condition (Bohr, 1995). As a result, UK prevalence estimates of FMS are 
lower than those for other countries. Hughes et al. (2006) estimated the overall 
prevalence of recorded FMS diagnoses to be 0.18% in a large primary care population in 
the UK. 
 
 
Historic Background 
 
FMS was first documented rigorously in the 1970s (Smythe, 1972). In 1990, the 
American College of Rheumatology (ACR) established classification criteria for FMS 
(Wolfe et al., 1990). These criteria are the basis for diagnosing and classifying FMS in 
the US, UK, Italy, Germany, Spain and Sweden. France’s medical community differs 
from those of other countries for endorsing the 1992 Declaration of Copenhagen 
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approach to FMS diagnosis (Jacobsen et al., 1993). The Declaration recommends using 
the two criteria established by ACR for research purposes, but permitting clinical 
flexibility on the tender point requirement when patients exhibit other symptoms of FMS. 
 
According to the World Health Organization (WHO) International Classification of 
Diseases, 9th Revision, Clinical Modification (ICD-9-CM) (2005), the diagnostic code 
for FMS is 729.1 (myalgia and myositis, unspecified). Following the establishment of 
FMS as a distinct diagnosis in the 1992 Declaration of Copenhagen, FMS was 
incorporated in the WHO's 10th Revision of the International Statistical Classification of 
Diseases and Related Health Problems (ICD-10) (1994). FMS (with fibrositis) appears in 
ICD-10 as "M79-O Rheumatism, unspecified", one of the many soft-tissue disorders not 
specified elsewhere. 
 
FMS is a syndrome of unknown etiology. Evidence shows that factors like stress and 
medical illness can be influential in the presentation of FMS’ in some but not all patients. 
A variety of neurotransmitter and neuroendocrine changes accompany FMS. These 
changes include reduced levels of biogenic amines, increased concentrations of excitatory 
neurotransmitters, alterations of hypothalamic-pituitary-adrenal axis and autonomic 
nervous system activity (Mease et al., 2005). 
 
Despite the lack of understanding of the causes of FMS, researchers are beginning to 
connect various theories that seek to explain the symptomatology of the condition. In 
recent years, research has focused on the neuroendocrine axis and its involvement in 
FMS. Altered patterns of basal and stimulated activity of several neuroendocrine axes 
have been discovered in FMS patients (Neeck et al., 2000). Researchers have noted that 
many FMS symptoms overlap with symptoms associated with neuroendocrine hormone 
deficiencies such as adult growth hormone deficiency and hypothyroidism (Burckhardt et 
al., 2005).  
 
Substance P is a neurotransmitter of pain, specifically type C pain fibers which are 
associated with slow or chronic pain. Researchers found that FMS patients have 
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approximately threefold higher concentrations of substance P when compared to healthy 
people (Russel 1994). In FMS patients it is suspected that substance P promotes the 
spread of slow pain and increases pain transmission (Lash et al., 2003). Decreased levels 
of norepinephrine have been found in FMS patients and therefore it is also implicated in 
the etiology of FMS.  
 
A dysfunction in the neurotransmitter, serotonin, is also among the possible etiologies of 
FMS. Tryptophan is serotonin’s precursor and together they ease pain and induce sleep. 
Studies have shown that levels of serotonin and tryptophan are low in FMS patients (Lash 
et al., 2003). 
 
Because the prevalence of FMS is higher in women, there has been speculation that sex 
steroid hormones may play a role in its etiology. However, no data suggests that altered 
ovarian hormone levels are a causative factor. In one study, pituitary and ovarian 
hormone levels and secretory patterns were measured in menstruating women with FMS 
during the follicular phase and were found to be normal (Korszun et al., 2000). 
 
 
Review of Similar or Related Studies 
 
Epidemiology 
It is important to have established criteria for FMS in epidemiological research. 
Consensus criteria for FMS were developed in 1990 (Wolfe et al., 1990). Prior to 1990, 
the signs and symptoms of FMS were classified and reclassified several times under 
various diagnostic labels (including fibrositis, psychogenic rheumatism, myogelosis, and 
muscle pain syndrome). As a result, epidemiological research was hampered. Since 1990, 
the criteria for FMS have become more standardized and epidemiological studies using 
the ACR criteria have been initiated (Linaker et al., 1999). There is only one large scale 
epidemiological survey (Wolfe et al., 1995) study and 2 administrative database studies 
(Robinson et al., 2003; Robinson et al., 2004) of FMS in the US. Based on Wolfe’s mail 
survey of 3,000 adults the overall prevalence of FMS is 2.0% in the US.  
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 Table 1: Prevalence Estimates of Fibromyalgia in the United States 
Reference Population  Prevalence Study design 
Wolfe et al., 
1995 
• Random sample of 
3,006 Witchita, KS 
residents 
• FMS overall 
prevalence was 2.0%  
• FMS prevalence for 
men estimated at 0.5% 
and women 3.4% 
• Survey with some in-person 
examination 
• Estimates based on the 
ACR criteria for FMS 
Robinson et al., 
2003 
Database of a Fortune 
100 manufacturer 
excluding employees 
over the age of 65 
and those enrolled in 
HMOs 
• 2.8% in the database 
• 61% of FMS claimants 
were female 
• Average age 46 years 
• Administrative claims 
database 
• Patients identified by ICD-9 
codes 
Robinson et al., 
2004 
Database of a Fortune 
100 manufacturer 
excluding employees 
over the age of 65 
and those enrolled in 
HMOs 
• 2.8% in the database 
• 9.2% of FMS patients 
had a claim for depression 
(note much smaller than 
anticipated) 
• 59% of FMS 
claimants were female 
• 72% of FMS + 
depression claimants were 
women 
• Administrative claims 
database 
• Patients identified by ICD-9 
codes 
 
 
In Europe, a number of studies were identified that provided epidemiological data on the 
prevalence of FMS. The results of these studies are summarized in Table 2. The 
prevalence of FMS in the general population from all the studies ranged from 0.18% to 
7.42%, with an average estimate of 2.42%. Although there are prevalence data for FMS 
for the European countries, the criteria defining FMS and the characteristics of samples, 
such as age and gender requirements vary, making direct comparison of prevalence 
across studies difficult.  
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Table 2: Summary of the Prevalence of Fibromyalgia 
Country Study Population Sample Size Prevalence  Study 
France Non-institutionalized adults 
(>15 years) 
N = 1,018 7.42% 
Women: 9.5% 
Men: 3.86% 
Myon and Taieb, 
2004 
Germany General population- female 
residents aged 35 to 74 
years. 
N = 653 5.5%  Schochat et al.,  
2003 
Italy General population – aged 
≥ 18 years 
N = 3,662 2.22% Salaffi et al.,  
2005 
Spain General population–
subjects aged ≥ 20 years  
 
N = 2,998 
 
Overall: 2.4% 
Age bands: 
20-29: - 
30-39: 1.6% 
40-49: 4.9% 
50-59: 3.7% 
60-69: 2.9% 
70-79: 2.9% 
Women: 4.2% 
Men: 0.2% 
Carmona et al., 
2001a 
 
 Rheumatology outpatient 
offices 
 
N = 1,134 
 
Overall: 12% 
Women: 15.5 
Men: 2.2% 
Gamero Ruiz et al.,
2005 
 
 
 Patients in a health clinic N = 685 Overall: 7.75% Ganuza et al.,  
2002 
UK Patients in a large primary 
care population 
Sample 
represents ~4.6% 
of the UK 
population 
0.18% Hughes et al.,  
2006 
 
 
Treatment  
Currently, FMS cannot be cured. Therefore, the goal of FMS treatment is to relieve 
symptoms and restore function. FMS is considered a chronic disease and therefore must 
be controlled using an approach of lifelong management (Clauw et al., 2003). The goal of 
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FMS treatment is to develop an individualized treatment approach that takes into account 
the nature of the patient’s FMS symptoms and their severity, the level of function and 
stressors, and the presence of medical and psychiatric co-morbidity (Arnold, 2006). 
 
Treatment should initially focus on verifying the diagnosis of FMS, validating the 
symptoms, and involving the patient in disease management. It is important to confirm 
diagnosis and educate the patient regarding the disease and its symptoms because 
education facilitates patient adherence to treatment and validates the disease. It is also 
important to identify comorbid conditions and take them into account when creating a 
treatment regimen. A FMS treatment regimen should incorporate multiple strategies and 
include both pharmacologic and non-pharmacologic therapies. For example, an 
appropriate treatment regimen may include basic education about FMS, low-dose 
antidepressants for sleep, an exercise program, non-pharmacologic strategies for pain and 
stress management (Karin et al., 2002).  
 
A variety of pharmacologic treatments have been used to alleviate FMS symptoms. The 
following are the American Pain Society’s recommendations for the pharmacologic 
treatment of FMS patients (Burckhardt et al., 2005).  
 
American Pain Society’s Recommendations For The Pharmacologic Treatment 
Of FMS 
1. For initial treatment of FMS, prescribe tricyclic antidepressants (TCA) or 
cyclobenzaprine for sleep at bedtime.  
2. For pain relief, use selective serotonin reuptake inhibitors (SSRIs) alone or in 
combination with tricyclics. 
3. Non-steroidal anti-inflammatory (NSAIDs) should not be used as the primary pain 
medication for people with FMS. 
4. Tramadol (atypical opioid) for pain relief. Tramadol can be used alone or in 
combination with acetaminophen. The dose should be increased slowly over time 
and should be tapered gradually when discontinued. 
5. Opioids should be used only after all other pharmacological and non-
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pharmacological therapies have been exhausted. 
6. For sleep disturbances, sleep and anti-anxiety medications such as trazodone, 
benzodiazepines, nonbenzodiazepine sedatives, or L-dopa and carbidopa are 
recommended.  
 
 
Lyrica is currently the only drug that is licensed for the treatment of FMS in the US and 
no drug(s) are licensed for treatment of FMS in the UK; however, there are a large 
number of drug classes that are used off-label to manage the condition. These include 
opioids, TCAs, SSRIs, and opiate receptor agonists. Patients with FMS tend to be 
sensitive and/or relatively intolerant to medications; therefore, it is advisable to begin 
with low doses and with the least number of side effects. All medications should be 
reviewed at regular intervals to monitor their efficacy (Fibromyalgia Association UK, 
2004).  
 
A study by Hughes et al. (2006) examined prescribing practice for patients who had been 
diagnosed with FMS in the UK. All patients with a recorded diagnosis of FMS were 
identified. A non-FMS control group (with 10 controls per case) was generated by 
matching subjects for index date, practice, sex, and year of birth. Overall rates of 
prescriptions were significantly higher in FMS cases compared to controls (at 6 months 
prior to diagnosis, 1,100 prescriptions per 100 person-years in FMS cases compared with 
450 prescriptions per 100 person-years in controls).  
 
In the one year prior to FMS diagnosis, rates of prescription for TCAs rose sharply and 
peaked at 35 prescriptions per 100 person-years at diagnosis (compared with two 
prescriptions per 100 person-years in controls). Thereafter, prescriptions for TCAs 
declined sharply to control levels. Prescription patterns for SSRIs were similar but less 
pronounced. Rates of prescriptions for NSAIDs rose steadily from 10 years prior to FMS 
diagnosis, and following a brief dip, continued to rise (to 250 prescriptions per 100 
person-years) by 4 years after FMS diagnosis (Hughes et al., 2006).  
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The Fibromyalgia Association UK (2004) also suggests that a combination of non-
pharmacological and pharmacological treatments are more helpful in managing FMS 
symptoms and daily functioning, than pharmacological treatment alone (Fibromyalgia 
Association UK, 2004). The non-pharmacological treatments recommended are presented 
in Table 3. 
 
Table 3: Examples of Non-pharmacological Treatments for Fibromyalgia in the UK 
Treatment  Notes 
Cognitive Behavioral Therapy (CBT) This helps patients to understand their pain and 
develop coping strategies; this has been shown to be 
effective. 
Body conditioning and exercise management A physiotherapist with an understanding of 
fibromyalgia will advise patients on different types 
of exercise. 
Activity scheduling, activity/rest cycling and 
goal setting 
This manages activity in a way that uses energy 
wisely by prioritizing, planning, and pacing activity. 
Alternative Therapies 
? Osteopathy 
? Acupuncture 
? Massage therapy 
? Herbal remedies 
There is limited empirical research to substantiate the 
use of alternative therapies; however, more focused 
research is beginning to recognize physiological and 
emotional benefits of these interventions. 
Source: Fibromyalgia Association UK, 2004. 
 
 
Quality of Life  
Since women comprise the majority of the FMS patient population, most of the literature 
focuses on the impact that FMS has on women’s lives, especially with regard to issues 
such as employment and family life (Reisine et al., 2003). Evidence of physician-patient 
discordance exists across both genders, and male FMS patients commonly report 
delaying treatment for fear of not being believed or taken seriously (Paulson et al., 2002). 
Moreover, there is conflicting evidence of symptom severity as experienced by male 
patients versus female patients (Reisine et al., 2003; Wolfe et al., 1995).  
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Patients with FMS often experience a negative impact on quality of life (QoL) issues 
such as personal relationships, career (Reisine et al., 2003), mental health (Bernard et al., 
2000), daily activities (Martinez et al.,1995), bodily pain and vitality (Bernard et, al., 
2000). Treatments that entail physical training are purported to bring about improvements 
in QoL in spite of the difficulties presented by chronic pain in maintaining a high level of 
physical fitness (Valim et al., 2003). FMS impacts all aspects of daily physical 
functioning; however, the most pressing issues for FMS patients appear to be the impact 
of chronic pain on their emotional health and social functioning (Bernard et, al., 2000). 
For instance, FMS patients often experience acute anxiety and depression, and their pain 
is exacerbated by fatigue (Affleck et al., 1996). Additionally, patients typically 
experience a loss of social support networks because their efforts to maintain them are 
hampered by the loss of vitality caused by chronic pain (Bernard et, al., 2000; Soderberg 
et al., 2002). Because FMS causes are poorly understood and there is no known cure, 
FMS patients also suffer the effects of medical and social isolation (Cudney et al., 2002).  
 
Cost of illness 
Data on the direct costs associated with the management of FMS were not available for 
the UK. Although the literature search identified no articles or Internet resources that 
provided direct cost estimates of FMS in UK, there were 8 US cost studies. The results of 
the US costs studies are summarized in Table 4 with the total estimated US annual direct 
medical costs for FMS per patient range from $2,274-$4,393 and indirect costs range 
from $1,394-$3,411. It is important to note that only one study provided an estimate for 
annual direct non-medical costs of $724. When the cost of the comorbidity of depression 
was added, the estimated annual direct medical costs range from $7,328 - $8,686 and 
indirect costs range from $3,212 - $7,328. In general, based on an analysis by Greenberg 
et al. (2003) almost half the economic loss associated with FMS is due to work loss. The 
rate of absenteeism amongst patients with FMS is 1.9 times greater than that of the 
average employee in their study. For employees with both FMS and depression, the rate 
of absenteeism is 3.4 times higher. Since the 2003 study by Greenberg et al. (2003) did 
not include the costs associated with presenteeism, it is likely that the total burden of 
disease to US employers is much higher than that found in their study. In Robinson et al. 
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(2004) study, employees in the plan were significantly more likely to file a disability 
claim for any reason (45% vs 22%) compared to the average employee. 
 
It is also worth noting that the majority of disability claims and medical costs are not 
directly related to FMS but are related to comorbid diseases or other conditions. 
Robinson found that only 1% of FMS employees filed a claim related to FMS and only 
2% of the employers total costs were tied to a FMS diagnosis (Robinson et al., 2004). In 
Robinson’s follow-up study which examined comorbid depression the total costs of 
treating FMS patients with major depressive disorder (MDD) were estimated at $11,899 
in 1998 (Greenberg et al. 2003). In Wolfe et al. (2004) study, rheumatoid arthritis (RA) 
with comborbid FMS was more expensive than RA alone ($6,447 versus $4,687). Wolfe 
et al. (1997) confirm the findings that comorbid conditions contribute significantly to 
costs. His multivariate regression found 3 significant factors that were associated with 
total costs: the number of comorbidities, disability as measured by the Health Assessment 
Questionnaire (HAQ) and global disease severity.  
 
Resource utilization of FMS patients is higher than typical insurance beneficiaries. 
Robinson et al. (2004) found that FMS claimants had 2.6 times more medical claims than 
the average beneficiary. Moreover, 45% of the FMS claimants had at least one claim for 
other diseases of the ‘musculoskeletal and connective tissue’ compared to 16% in the 
sample of average beneficiaries and were more likely to use prescription medications. 
Approximately 76% of FMS claimants were seen a least once by a general practitioner 
over a years time period. In contrast, Wolfe et al. (1997) found a much higher level of 
resource use:  an average of 9.8 physician visits per year. The difference in these 
estimates is that Wolfe’s study was potentially better at capturing these estimates as it did 
not rely on claims data. 
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Table 4: Cost of Illness Studies in Fibromyalgia Patients 
Reference Population  Cost (direct, indirect) 
Greenberg et al., 2003 Company employees 
under the age of 65  who 
are enrolled in a company 
sponsored fee for service 
health plan and are 
eligible for disability 
benefits 
• Total medical costs (work loss cost): 
? 10% sample of average employees = 
$2,346.10 ($1,698.90) 
? FMS only = $3,148.80 ($3,411.20) 
? FMS + Depression = $7,328 ($7,328) 
Robinson et al., 2003 Database of a Fortune 100 
manufacturer excluding 
employees over the age of 
65 and those enrolled in 
HMOs 
• Total annual medical costs (disability/ 
absenteeism cost): 
? Average employees = $1,934 
($330.64/$221.25) 
? FMS only = $4,393.36 ($1,016.56/$535.05) 
Robinson et al., 2004 Database of a Fortune 100 
manufacturer excluding 
employees over the age of 
65 and those enrolled in 
HMOs 
• Total annual medical costs (workplace cost): 
• Average employees = $1,939.08 ($546.92) 
• FMS only = $3,768.99 ($1,394.01) 
• FMS + Major Depression = $8,686.27 
($3,212.73) 
Wolfe et al., 1997 538 patients (mean age 
=49, 89% female, 86% 
white) 
• Annual costs 
? $882 = hospitalization 
? $731 = drugs 
? $340 = outpatient visits 
? $320 = other 
• Total direct medical = $2,274 
Wolfe and Michaud, 
2004 
 
2,078 RA patients with 
FMS (mean age =59, 
84.5% female, 88% 
white) 
• Cost per 6 months in FMS + RA 
? $1,324 = hospitalization 
? $3,776 = drugs 
? $1,377 = outpatient 
• $6,477 = total costs 
Wassem and Hendrix, 
2003 
102 FMS patients 
attending a FMS support 
group meeting (mean age 
54 years, 83% female) 
• Annual costs 
? $2,943 = Direct medical 
? $724 = Direct non-medical 
? $1,833 = Indirect  
Bombardier and 
Buchwald, 1996 
402 patients (147 Chronic 
Fatigue syndrome, 28 
• For FMS patients only: 
? Mean number of medical visits a year =25.7 
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Reference Population  Cost (direct, indirect) 
FMS and 68 Chronic 
Fatigue Syndrome and 
FMS (mean age 39 years, 
75% female) 
? Mean number of diagnosis = 1.7 
? 32% saw a chiropractor 
? 39% saw a psychiatrist 
? 25% saw a naturopath/homeopath 
? 21% saw an acupuncturist 
Bigatti and Cronana, 
2002 
135 male spouses of FMS 
patients matched to an 
equal number of spouses 
of women with no FMS 
• Annual Direct medical cost of spouses whose 
wife has FMS = $1,108 
• Annual Direct medical cost of spouses whose 
wife does not have FMS = $1,424 
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CHAPTER THREE: METHODOLOGY 
 
Description of Approach  
 
The approach of this study built upon the work of Hughes et al. (2006) by providing a 
detailed examination of resource utilization among FMS patients in the UK. This study 
was classified into 2 different analyses: comparison of resource utilization 12 months 
before and after the FMS diagnosis; and the characteristics of the patient population in 
terms of its epidemiology, demographics, and comorbidities, in the UK. The results of 
this study provided a comprehensive characterization of FMS, its treatments, and 
associated costs. 
 
 
Research Design 
 
This study was a pre-post retrospective database analysis of FMS patients. Among 
patients with FMS during the study period, an analysis was conducted to compare levels 
of medical resource utilization, pharmacy utilization, and associated costs incurred during 
the period 12-month prior to the first observed (index) diagnosis with those incurred 
during the period 12-month following the index diagnosis. 
 
 
Selection of Subjects 
 
For patients in the study cohort, an index date was defined as the date of the first 
observed FMS diagnosis that took place between January 1, 1999, and December 31, 
2005. The study cohort was deemed acceptable as defined by the data quality criteria in 
the General Practice Research Database (GPRD). The patients’ index date was also be an 
incident FMS diagnosis (no prior record of FMS), and patients also had a minimum 
registration duration of 12 months pre-index date.  
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Sample/Population of Interest 
 
Construction of the study sample for this analysis began with the selection of patients 
from the GPRD. The study cohort included all patients with any diagnosis of FMS 
between January 1, 1999, and December 31, 2005. Patients with FMS were identified 
based on the following Read/Oxford Medical Information System codes: N248.00, 
N239.00, 7339F (Fibromyalgia), and N241200 (Fibromyositis, not otherwise specified). 
 
 
Outcome Measures 
 
The primary outcomes that were analyzed in this study included demographic 
characteristics; medical resource utilization, including GP visits and referrals to 
secondary-care specialists and hospitals; utilization patterns for specific 
pharmacotherapies; and overall prevalence of 
comorbidities. The targeted comorbidities and referrals were established by an initial 
investigation of the data.  
 
Pharmacotherapy resource utilization was examined in 10 pharmacotherapy categories 
identified a priori as relevant to patients with FMS based on the literature; these included 
anticonvulsants, benzodiazepines, centrally acting analgesics, muscle relaxants, 
nonbenzodiazepine sleep medications, NSAIDs, SNRIs, SSRIs, systemic corticosteroids, 
and TCAs (Goldenberg et al., 2004). 
 
This study also used UK costing data based on the medical and pharmacotherapy 
resource utilization data to calculate the cost of FMS in the 12-month prior to and 
following the FMS diagnosis. Results of these analyses provided a comprehensive 
characterization of medical and pharmacotherapy treatment for FMS, as well as the costs 
associated with FMS among UK primary care patients.  
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Procedures 
 
Demographic characteristics that were analyzed included age (continuous and 
categorical), gender, and geographic location of the patient’s GP. A visit to the GP was 
assumed for each unique date indicating a clinical event. Results on GP utilization was 
stratified by visits for all causes as well as by visits related to the specific comorbidities 
of interest. The overall number and percentage of patients with at least one referral to a 
hospital or to a secondary-care specialist was estimated and reported. Results on referrals 
to secondary-care specialists were further stratified by specialty type (e.g., rheumatology, 
mental health, gastroenterology, orthopaedics or other specialties). 
 
The overall number and percentage of patients that use any prescription 
pharmacotherapies was estimated and reported. Patterns of pharmacotherapy use (e.g., 
average of number of pharmacotherapy, duration, discontinuation, and concomitant use) 
were quantified for the specific drug classes that have been identified as relevant to FMS 
in the literature. The observed total costs will also be summarized for FMS patients pre- 
and post-index date. 
 
 
Data Analysis 
 
The statistical approaches that were implemented to address the study objectives 
described above were summarized in this section. Descriptive analyses entailed the 
tabular display of mean values of continuous variables of interest. Descriptive analyses of 
categorical variables entailed the tabular display of frequency distributions. The statistical 
significance of descriptive differences in the outcomes of interest between the pre- and 
post-diagnosis time periods within the study cohort was measured using t-tests and χ2 
tests, with results reported as P values (significance level < 0.05).  
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Institutional Review Boards (IRBs) 
 
The GPRD data was provided by Research Triangle Institute (RTI). RTI holds a Federal-
Wide Assurance (FWA) from the Department of Health and Human Services' Office for 
Human Research Protections (FWA #3331) that allows them to review and approve 
human subject protocols through their internal Institutional Review Boards (IRBs). RTI’s 
FWA requires IRB review for all studies that involve human patients, regardless of the 
funding source. The GPRD data was ruled as exempt from IRB review by an IRB chair 
and designated IRB member on August 2, 2006. RTI currently has three IRB committees 
and these IRBs have been reviewed by the FDA and are fully compliant with applicable 
regulatory requirements. The committee assigned a given research study reviews the 
study protocol and consent documents to ensure both are in compliance with the 21 CFR 
50 Federal regulations that govern human subjects research. The committee can approve, 
approve with modifications, or disapprove any research protocol based on the compliance 
of the protocol and consent procedures with these regulations.  
 
 
Hypothesis 
 
The primary hypothesis of this pre-post study was that FMS patients will have an 
increase in medication resource utilization after the initial FMS diagnosis compared to 
the 12 months prior to the FMS diagnosis.  
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CHAPTER FOUR: RESULTS 
 
Demographics 
 
The pre-post analysis was performed on a subset of patients from the FMS cohort (n = 
5,444) and the analyses assessed within-patient differences for 12 months prior to 
compared with 12 months after the date of the first observed FMS diagnosis (index date). 
The average age of FMS patients included in the pre-post analysis was 48.5 years. More 
than 60% of patients were over age 45 years. More than 83% of patients were women. By 
design, all patients had a total of 2 years of follow-up, 12 months prior to the index date 
(pre-index period) and 12 months following the index date (post-index period). Table 5 
summarizes the demographics. 
 
Table 5: Demographics  
Parameter Fibromyalgia 
 
Gender  
Female 4,529 (83.2%) 
Male 915 (16.8%) 
Age at index date  
Mean (SD*) 48.5 (13.3) 
Median 49 
Range 7.0 - 90.0 
Age group at index date  
0 to 17 56 (1.0%) 
18 to 24 137 (2.5%) 
25 to 34 571 (10.5%) 
35 to 44 1,310 (24.1%) 
45 to 54 1,649 (30.3%) 
55 to 64 1,100 (20.2%) 
65 or Higher 621 (11.4%) 
*SD = standard deviation. 
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Comorbidities 
 
Table 6 presents the comorbidities and comorbidity classes that occurred in ≥ 5% of 
patients with FMS. The most common class of comorbidities were Musculoskeletal & 
Connective Tissue Disorders. Within this class, there were a higher number of patients 
with arthralgia (17.3% vs. 10.7%), back pain (12.6% vs. 10.3%), neck pain (7.2% vs. 
6.0%), pain in limb (6.4% vs. 5.4%) and myalgia (5.7% vs. 2.7%) in the pre-index period 
compared to the post-index period. 
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Table 6: Comorbidities (Occurring in ≥ 5% of Patients in the Pre-Period) in the 12 
Months Prior to and After FMS Index Period 
Comorbidities 
 
Pre–Index  
Period 
Post–Index  
Period 
P Value 
 
Musculoskeletal and connective tissue 
disorders 
1,273  
(23.38%) 
898  
(16.50%) 
<0.001 
Arthralgia 943  
(17.32%) 
584  
(10.73%) 
<0.001 
Back pain 687  
(12.62%) 
562  
(10.32%) 
<0.001 
Neck pain 392  
(7.20%) 
325  
(5.97%) 
0.012 
Pain in limb 349  
(6.41%) 
295  
(5.42%) 
0.033 
Myalgia 308  
(5.66%) 
147  
(2.70%) 
<0.001 
General disorders and administration site 
conditions 
1,077  
(19.78%) 
999  
(18.35%) 
0.086 
Pain NOS 580  
(10.65%) 
401  
(7.37%) 
<0.001 
Fatigue 375  
(6.89%) 
239  
(4.39%) 
<0.001 
Pre-existing condition improved 299  
(5.49%) 
424  
(7.79%) 
<0.001 
Chest pain 310  
(5.69%) 
282  
(5.18%) 
0.249 
Drug hypersensitivity 234  
(4.30%) 
307  
(5.64%) 
0.001 
Respiratory, thoracic and mediastinal 
disorders 
833  
(15.30%) 
1,000 
 (18.37%) 
<0.001 
Cough 404  
(7.42%) 
494  
(9.07%) 
0.002 
Upper respiratory tract infection NOS 307  
(5.64%) 
359  
(6.59%) 
0.043 
Lower respiratory tract infection NOS 260  
(4.78%) 
308  
(5.66%) 
0.044 
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Comorbidities 
 
Pre–Index  
Period 
Post–Index  
Period 
P Value 
 
Pharyngitis 284  
(5.22%) 
294  
(5.40%) 
0.677 
Surgical and medical procedures 685  
(12.58%) 
755  
(13.87%) 
0.065 
Hormone replacement therapy 256  
(4.70%) 
220  
(4.04%) 
0.098 
Contraception NOS 174  
(3.20%) 
142  
(2.61%) 
0.071 
Gastrointestinal disorders 755  
(13.87%) 
912  
(16.75%) 
<0.001 
Abdominal pain NOS 336  
(6.17%) 
373  
(6.85%) 
0.164 
Dyspepsia 260  
(4.78%) 
280  
(5.14%) 
0.389 
Psychiatric disorders 673  
(12.36%) 
842  
(15.47%) 
<0.001 
Depression 339  
(6.23%) 
404  
(7.42%) 
0.017 
Anxiety 205  
(3.77%) 
219  
(4.02%) 
0.496 
Nervous system disorders 665  
(12.22%) 
753  
(13.83%) 
0.019 
Headache 219  
(4.02%) 
221  
(4.06%) 
0.924 
Vascular disorders 613  
(11.26%) 
719  
(13.21%) 
0.003 
Immune system disorders 575  
(10.56%) 
662  
(12.16%) 
0.013 
Drug hypersensitivity 234  
(4.30%) 
307  
(5.64%) 
0.001 
Skin and subcutaneous tissue disorders 523  
(9.61%) 
636  
(11.68%) 
<0.001 
Reproductive system and breast disorders 463  
(8.50%) 
543  
(9.97%) 
0.011 
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Comorbidities 
 
Pre–Index  
Period 
Post–Index  
Period 
P Value 
 
Metabolism and nutrition disorders 352  
(6.47%) 
462  
(8.49%) 
<0.001 
Cardiac disorders 289  
(5.31%) 
388  
(7.13%) 
<0.001 
Injury, poisoning and procedural 
complications 
278  
(5.11%) 
265  
(4.87%) 
0.576 
NOS = not otherwise specified 
 
 
GP Visits and Referrals 
 
The mean number of GP visits for arthralgia was slightly higher in the post–index date 
period (1.76) compared with the pre–index date period (1.69). Similarly, patients who 
had a visit for back pain in the pre–index date period had 1.77 visits on average compared 
to 1.84 visits in the post-index period.  
 
Table 7 presents the number and percentage of patients with a referral to each of the 
30 most common specialties (occurring in ≥ 0.3% of FMS patients in the pre-period). In 
the pre–index period, 53.1% of patients had a specialist referral, with an average of 2.11 
referrals compared to 53.3% of patients and 2.09 referrals in the post-index period 
(difference not statistically significant). Rheumatology referrals were the most common, 
with 17.2% of patients in the pre–index date period and 10% of patients in the post–index 
date period receiving a referral (P < 0.001).  
 
In addition, the rate of hospital referrals was low in both the pre– and post–index date 
periods (2.0% and 2.4%, respectively, difference not statistically significant). 
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Table 7: Health Care Utilization (Specialist Referrals) 12 Months Prior to and After Index 
Period 
Pre–Index Period 
(N = 5,444) 
Post–Index Period 
(N = 5,444) Reason for 
Utilization 
 
 
 
N (%) 
 
Mean 
Referrals 
Total 
Referrals 
N (%) 
Mean 
Referrals 
Total 
Referrals 
ALL 2,892 
(53.1%) 
2.11 6,094 2,902 
(53.3%) 
2.04 5,915 
Rheumatology 939 
(17.2%) 
1.09 1,028 545 
(10.0%) 
1.1 597 
Other 444 (8.2%) 1.27 562 514 (9.4%) 1.24 638 
Diagnostic test and 
investigations 
404 (7.4%) 2.25 910 322 (5.9%) 2.28 735 
General medicine 382 (7.0%) 1.13 432 366 (6.7%) 1.17 428 
Radiology 330 (6.1%) 1.19 394 322 (5.9%) 1.28 411 
General surgical 326 (6.0%) 1.12 364 398 (7.3%) 1.08 430 
Trauma and 
orthopaedics 
288 (5.3%) 1.08 310 284 (5.2%) 1.1 313 
Physiotherapy 274 (5.0%) 1.12 308 325 (6.0%) 1.1 356 
Gynecology 216 (4.0%) 1.14 246 251 (4.6%) 1.08 270 
Ear, nose, and 
throat 
169 (3.1%) 1.11 188 170 (3.1%) 1.06 181 
Dermatology 138 (2.5%) 1.09 150 103 (1.9%) 1.1 113 
Ophthalmology 136 (2.5%) 1.02 139 145 (2.7%) 1.04 151 
Neurology 89 (1.6%) 1.06 94 101 (1.9%) 1.14 115 
Accident and 
emergency 
71 (1.3%) 1.24 88 53 (1.0%) 1.19 63 
Chemical 
pathology 
69 (1.3%) 1.51 104 63 (1.2%) 2.05 129 
Gastroenterology 65 (1.2%) 1.14 74 76 (1.4%) 1.09 83 
Adult psychiatry 59 (1.1%) 1.1 65 72 (1.3%) 1.11 80 
Cardiology 57 (1.0%) 1.04 59 71 (1.3%) 1.1 78 
Anaesthetics 46 (0.8%) 1.07 49 85 (1.6%) 1.22 104 
            32
Pre–Index Period 
(N = 5,444) 
Post–Index Period 
(N = 5,444) Reason for 
Utilization 
 
 
 
N (%) 
 
Mean 
Referrals 
Total 
Referrals 
N (%) 
Mean 
Referrals 
Total 
Referrals 
Urology 39 (0.7%) 1.08 42 49 (0.9%) 1.04 51 
Rehabilitation 33 (0.6%) 1.12 37 40 (0.7%) 1.13 45 
Mental illness 32 (0.6%) 1.06 34 46 (0.8%) 1.13 52 
Dietetics 26 (0.5%) 1 26 32 (0.6%) 1.06 34 
Non-referral report 26 (0.5%) 1.92 50 35 (0.6%) 2.06 72 
Chiropody 24 (0.4%) 1 24 42 (0.8%) 1.02 43 
Clinical psychology 24 (0.4%) 1.04 25 14 (0.3%) 1.21 17 
Obstetrics 21 (0.4%) 1.1 23 27 (0.5%) 1.07 29 
Haematology 20 (0.4%) 1.2 24 18 (0.3%) 1.5 27 
Plastic surgery 16 (0.3%) 1.06 17 28 (0.5%) 1.04 29 
Psychotherapy 15 (0.3%) 1 15 27 (0.5%) 1.04 28 
*The P value tests the probability that the mean difference equals 0. 
N (%) is calculated on patients experiencing at least one event. 
Mean visits are calculated for patients experiencing at least one event in the specified category. 
Mean per-patient difference is calculated by taking the mean of each patient's post-pre difference. 
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Pharmacotherapy Utilization 
 
In the pre–index period, 93.3% of patients were prescribed a pharmacotherapy from one 
of the 10 selected pharmacotherapy categories; in the post–index period, 97.7% of 
patients were prescribed a pharmacotherapy from one of these categories (P < 0.001). 
Table 8 presents the percentage of patients with at least one prescription for a 
pharmacotherapy in each of the 10 selected pharmacotherapy categories in the pre– and 
post–index periods; these data also are presented for specific drugs prescribed by ≥ 5% of 
patients in the pre–index period.  
 
Nonsteroidal anti-inflammatory drugs (NSAIDs) were the most commonly prescribed 
pharmacotherapy. More FMS patients were prescribed NSAIDs in the post-index period 
compared to the pre-index period (19.0% vs. 13.5% p-value < 0.001). The second most 
commonly prescribed pharmacotherapy category was systemic corticosteroids. There was 
also a significant increase in the number of FMS patients with a prescription for systemic 
corticosteroid in post–index period compared to the pre-index period (14.8% vs. 10.9%, 
p-value < 0.001). 
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Table 8: Pharmacotherapy Used by ≥ 5% of Patients with FMS 
Drug Class 
 
Pre–Index Period  
N (%) 
Post–Index Period  
N (%) 
P Value 
NSAIDS 734 (13.5%) 1,032 (19.0%) <0.001 
Systemic corticosteroids 592 (10.9%) 805 (14.8%) <0.001 
Centrally acting analgesics 472 (8.7%) 695 (12.8%) <0.001 
TCAs 300 (5.5%) 1,648 (30.3%) <0.001 
SSRIs 353 (6.5%) 612 (11.2%) <0.001 
Benzodiazepines 301 (5.5%) 358 (6.6%) 0.026 
Nonbenzodiazepine sleep 
medications 
165 (3.0%) 214 (3.9%) 0.011 
SNRIs 95 (1.7%) 154 (2.8%) <0.001 
Anticonvulsants 59 (1.1%) 181 (3.3%) <0.001 
Muscle relaxants 55 (1.0%) 95 (1.7%) 0.001 
NSAID = nonsteroidal anti-inflammatory drug 
SNRI = serotonin and norepinephrine reuptake inhibitor 
SSRI – selective serotonin reuptake inhibitor 
TCA = tricyclic antidepressants. 
 
 
Pharmacotherapy Utilization Patterns 
 
Table 9 shows the number and percentage of patients with FMS who used multiple 
categories of drugs from the selected pharmacotherapy list in the pre- and post-index 
periods. On average, FMS patients used fewer different drug categories in the pre–index 
date period compared with the post–index date period (2.2 vs. 2.7) and fewer unique 
medications (3.0 vs. 3.6). Table 9 also lists the number and percentage of patients who 
used the selected drug categories concurrently. FMS patients used more medications 
concurrently in the post-index period than in the pre-index period. Approximately 20% of 
FMS patients used two or more drug classes concurrently in the post-index period 
compared with 6.4%  in the pre–index date period (P < 0.001). Compared to the pre-
index period, more FMS patients had a concurrent prescription for three or more drug 
classes in the post-index period (13.8% vs. 5.4%, p-value < 0.001). 
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Table 9: Multiple Drug Use 
Drug Category 
Pre–Index 
Period 
Post–Index 
Period 
P Value 
Multiple medication use    
From 0 of the drug categories 652 (12.0%) 156 (2.9%) <0.001 
From 1 of the drug categories 838 (15.4%) 599 (11.0%) <0.001 
From 2 of the drug categories 845 (15.5%) 906 (16.6%) 0.144 
From 3 of the drug categories 669 (12.3%) 923 (17.0%) <0.001 
From 4 of the drug categories 448 (8.2%) 647 (11.9%) <0.001 
From 5 of the drug categories 215 (3.9%) 354 (6.5%) <0.001 
From 6 of the drug categories 94 (1.7%) 146 (2.7%) <0.001 
From 7 of the drug categories 23 (0.4%) 47 (0.9%) 0.004 
From 8 of the drug categories 7 (0.1%) 9 (0.2%) 0.617 
From 9 of the drug categories 0 (0.0%) 4 (0.1%) 0.045 
From 10 of the drug categories 652 (12.0%) 156 (2.9%) <0.001 
Concurrent medication use    
From ≥2 of the drug categories 351 (6.4%) 1,106 (20.3%) <0.001 
From ≥3 of the drug categories 294 (5.4%) 752 (13.8%) <0.001 
 
 
Duration of Therapy 
 
For FMS patients who received pharmacological treatment in both the pre- and post-
index periods, the average duration of therapy was highest for the serotonin and 
norepinephrine reuptake inhibitor (SNRI) drug class (241.1 and 264.4 days in the pre– 
and post–index periods, respectively: P < 0.001). The average duration of therapy was 
slightly lower for the selective serotonin reuptake inhibitor (SSRI) class, with 218.0 and 
233.1 days in the pre– and post–index periods respectively (P  =  0.001). 
 
The mean duration of therapy across all patients was the highest for NSAIDs (70.2 and 
87.0 days in the pre– and post–index periods, respectively; P < 0.001). Muscle relaxants 
had the lowest therapy duration across all patients (1.7 and 2.6 days in the pre– and post–
index periods, respectively; P < 0.001). 
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Table 10 presents the number and percentage of patients who discontinued therapy with 
the selected pharmacotherapy categories at various time points following the index date. 
For example, among the 2,023 patients that used TCAs in the post–index period, 65.4% 
discontinued therapy at some point over the 12 months following the index date and 
34.6% did not discontinue therapy. The discontinuation rate was the highest between 31-
60 days (22.5%). Overall discontinuation rate was the highest for NSAIDs (71.6%) and 
lowest for anticonvulsants (41.1%). Patients who discontinued pharmacotherapy had a > 
60 day gap between exhaustion of previous pharmacotherapy and the end of the 12-
month post-index period; therefore, FMS patients did not restart pharmacotherapy later in 
the year after discontinuing pharmacotherapy. 
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Table 10: Frequency Distribution of Post–Index Discontinuation of Prescription Therapy 
Drug Class at 
Index Date 
N* 
1-30  
Days 
31-60 
Days 
61-90 
Days 
91-180 
Days 
181-305 
Days 
Total 
Discontinued 
TCAs 2,023 275 
(13.59%) 
455 
(22.49%) 
165 
 
(8.16%) 
260 
(12.85%) 
168  
(8.30%) 
1,323  
(65.40%) 
NSAIDS 1,952 521 
(26.69%) 
367 
(18.80%) 
121  
(6.20%) 
223 
(11.42%) 
165 
(8.45%) 
1,397  
(71.57%) 
Centrally acting 
analgesics 
1,157 236 
(20.40%) 
139 
(12.01%) 
66  
(5.70%) 
109 
 (9.42%) 
94  
(8.12%) 
644  
(55.66%) 
Systemic 
corticosteroids 
849 183 
(21.55%) 
159 
(18.73%) 
51  
(6.01%) 
124 
(14.61%) 
78  
(9.19%) 
595  
(70.08%) 
SSRIs 753 99  
(13.15%) 
72  
(9.56%) 
47  
(6.24%) 
93  
(12.35%) 
81  
(10.76%) 
392  
(52.06%) 
Benzodiazepines 386 57  
(14.77%) 
37  
(9.59%) 
12  
(3.11%) 
32  
(8.29%) 
22  
(5.70%) 
160  
(41.45%) 
Nonbenzodiazepine 
sleep medications 
171 41 
 
(23.98%) 
17  
(9.94%) 
13  
(7.60%) 
15  
(8.77%) 
6  
(3.51%) 
92  
(53.80%) 
Anticonvulsants 129 15 
 
(11.63%) 
16  
(12.40%) 
2  
(1.55%) 
12  
(9.30%) 
8  
(6.20%) 
53  
(41.09%) 
SNRIs 113 12 
 
(10.62%) 
13  
(11.50%) 
5  
(4.42%) 
10  
(8.85%) 
8  
(7.08%) 
48  
(42.48%) 
Muscle relaxants 55 22  
(40.00%) 
7  
(12.73%) 
4  
(7.27%) 
3  
(5.45%) 
3  
(5.45%) 
39  
(70.91%) 
* N = number of patients receiving the specified treatment on the index day 
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Medical and Pharmacotherapy Costs 
 
Table 11 and Table 12 present patient costs for the pre– and post–index periods. Because 
the timeframe for analysis is 12 months in the pre– and post–index periods, these costs 
represent annualized estimates. FMS patients had a 20.3% increase in GP visit costs in 
the post-index period compared to the pre-index period (£346.84 vs. £288.41, p-value < 
0.001).  
 
In addition, the annual per-patient pharmacotherapy cost was £88.15 in the pre–index 
period compared with £118.62 (increased by 34.6%) in the post–index period. TCAs had 
the highest percentage change between the pre– and post–index periods (increased by 
80.5%), followed by anticonvulsants (77.6% increase). 
 
After controlling for age, gender, and geographic region, patients incurred £75 more per 
year in GP visits and pharmacotherapy costs in the post–index period compared with the 
pre–index period (P < 0.001). These patients incurred £22 more in pharmacotherapy 
expenses and £53 more in GP visits in the post–index period compared with the pre–
index period. After controlling for demographic characteristics, centrally acting 
analgesics had the largest pre-to-post difference among all of the drug categories. Among 
GP visit reasons, arthralgia had the largest difference (reduction in £2.5 annually).  
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Table 11: Annualized Patient Costs for General Practitioner Visit (With an Annualized 
Cost ≥ £1 for Patients in the Pre–Index Period) 
Mean Per-Patient Cost 
General Practitioner 
Visit Reason Pre–Index 
Period 
Post–Index 
Period 
Difference 
Percentage 
Change 
P Value* 
All £288.41 £346.84 £58.43 20.30% <0.001 
Arthralgia £10.30 £6.93 –£3.38 –32.80% <0.001 
Back pain £7.71 £6.28 –£1.43 –18.50% <0.001 
Pain NOS £5.30 £3.97 –£1.33 –25.10% <0.001 
Cough £4.10 £4.70 £0.61 14.80% 0.016 
Depression £3.92 £4.46 £0.55 14.00% 0.044 
Hormone replacement 
therapy 
£3.69 £3.56 –£0.12 –3.40% 0.5 
Neck pain £3.38 £2.71 –£0.67 –19.80% 0.002 
Abdominal pain NOS £3.13 £3.36 £0.23 7.30% 0.321 
Chest pain £2.85 £2.35 –£0.50 –17.40% 0.012 
Fatigue £2.71 £1.71 –£1.00 –36.80% <0.001 
Contraception NOS £2.67 £2.53 –£0.14 –5.30% 0.363 
Pre-existing condition 
improved 
£2.65 £3.41 £0.76 28.80% <0.001 
Pain in limb £2.61 £2.09 –£0.52 –19.90% 0.004 
Lower respiratory tract 
infection NOS 
£2.33 £2.82 £0.48 20.70% 0.006 
Myalgia £2.27 £1.09 –£1.18 –52.00% <0.001 
Pharyngitis £2.10 £2.08 –£0.02 –0.90% 0.907 
Dyspepsia £2.09 £2.21 £0.12 5.90% 0.451 
Anxiety £2.03 £2.07 £0.04 2.00% 0.813 
Physiotherapy £1.99 £2.10 £0.11 5.50% 0.614 
Upper respiratory tract 
infection NOS 
£1.96 £2.31 £0.35 18.00% 0.017 
Headache £1.85 £1.59 –£0.25 –13.70% 0.105 
Insomnia £1.63 £1.74 £0.11 6.50% 0.493 
Drug hypersensitivity £1.51 £1.89 £0.38 25.20% 0.004 
Urinary tract infection NOS £1.47 £1.39 –£0.08 –5.60% 0.532 
            40
Mean Per-Patient Cost 
General Practitioner 
Visit Reason Pre–Index 
Period 
Post–Index 
Period 
Difference 
Percentage 
Change 
P Value* 
Osteoarthritis NOS £1.25 £1.06 –£0.19 –15.40% 0.144 
General symptom NOS £1.22 £1.18 –£0.05 –3.80% 0.699 
Sinusitis acute NOS £1.22 £1.40 £0.18 14.70% 0.127 
Asthma NOS £1.19 £1.32 £0.13 10.80% 0.315 
Constipation £1.17 £1.52 £0.35 29.80% 0.016 
Diarrhea NOS £1.17 £1.38 £0.22 18.50% 0.098 
Dyspnea NOS £1.08 £1.30 £0.22 20.30% 0.078 
Migraine NOS £1.04 £1.06 £0.02 2.20% 0.833 
Acupuncture £1.03 £1.83 £0.80 77.70% <0.001 
* The P values test the probability that the mean per-patient difference equals 0. 
The percentage change is calculated with the pre–index date period as a reference. 
Hospitalizations and referrals are not included in the costing, as further details on these are not recorded. 
NOS = not otherwise specified
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Table 12: Annualized Patient Pharmacotherapy Costs  
Mean Per-
Patient Cost 
    
Pharmacotherapy Category 
Pre–Index 
Date 
Post–Index 
Date 
Difference 
Percentage 
Change 
P Value* 
All £88.15 £118.62 £30.48 34.60% <0.001 
Systemic corticosteroids £27.52 £33.64 £6.12 22.30% 0.247 
NSAIDS £21.93 £29.09 £7.16 32.70% <0.001 
Centrally acting analgesics £14.60 £20.73 £6.13 42.00% <0.001 
SNRIs £6.94 £9.03 £2.09 30.20% <0.001 
TCAs £5.41 £9.76 £4.35 80.50% <0.001 
SSRIs £4.99 £6.59 £1.61 32.30% <0.001 
Anticonvulsants £2.65 £4.71 £2.06 77.60% <0.001 
Benzodiazepines £2.65 £3.06 £0.41 15.70% 0.045 
Nonbenzodiazepine sleep 
medications 
£0.96 £1.29 £0.32 33.30% <0.001 
Muscle relaxants £0.51 £0.72 £0.21 40.70% 0.078 
* The P values test the probability that the mean per-patient difference equals 0.
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CHAPTER FIVE: DISCUSSION 
 
This study supports findings from previous studies indicating that FMS predominantly 
affects women (de Girolamo, 1991; Hughes et al., 2006), and tends to emerge in middle-
aged individuals (Kahn, 2003; Hughes et al., 2006). Not unexpectedly, given that FMS is 
often accompanied by comorbidities (Wolfe et al., 1990) and is diagnosed based on the 
presence of widespread pain (particularly in designated tender points) (Wolfe et al., 
1990), patients with FMS had significantly lower rates of musculoskeletal and connective 
tissue disorders (such as arthralgia, back pain, neck pain, chest pain, pain in limb, and 
myalgia) after being diagnosed and treated for FMS compared to the 12 months prior to 
being diagnosed. Furthermore, this study also found that patients had a higher rate of 
depression and anxiety after being diagnosed with FMS than prior to the diagnosis. This 
finding is consistent with studies that have linked FMS with abnormalities in the 
neurotransmitters serotonin and norepinephrine (Russell et al., 1992a, Russell et al., 
1992b; Schwarz et al., 1999; Yunus et al., 1992). 
 
With respect to medical resource utilization, this study found that patients with FMS had 
an average of 12.1 GP visits in the 12-month period prior to the FMS diagnosis and 13.9 
visits in the 12-month period after the diagnosis, which may reflect increased visits for 
pharmacological treatment following diagnosis. GP visits for specific conditions were 
also higher after being diagnosed with FMS than in the 12-month prior period. Similar to 
the finding with respect to comorbidities, patients with FMS had significantly higher 
rates of GP visits for a variety of pain-related conditions (including arthralgia, back pain, 
pain NOS, neck pain, chest pain, pain in limb, abdominal pain NOS), as well as anxiety 
and depression.  
 
Like this study, Hughes et al. (2006) found that pain-related conditions (including chest 
pain and headache), as well as anxiety and depression, were among the most common 
reasons that patients with FMS visited the GP. Sleep disturbance, dizziness, and irritable 
bowel syndrome also were among the most common reasons of those considered by 
Hughes et al. (2006) that patients with FMS visited GPs. However, one limitation to 
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Hughes et al. (2006) study was that it examined GP visits only for specific clinical 
symptoms identified a priori, which limits comparisons between the two studies. 
 
There were no statistically significant differences in the rate of hospital referrals between 
the pre– and post–index date periods. In addition, the rates of specialist referrals in the 
pre– and post–index periods were similar. Similarly, Hughes et al. (2006) found that 
specialist referrals were significantly higher among patients with FMS relative to control 
patients (at 6 months prior to diagnosis: 130 referrals per 100 person-years for patients 
with FMS, vs. 57 referrals per 100 person-years for control patients). Rheumatology was 
the most common specialist referral for patients with FMS in this study as well as in the 
Hughes et al. (2006) study. As was the case with the GP visit rates, the lower referral 
rates found in this study relative to the Hughes et al. (2006) study can be attributed to the 
differences in the periods examined in each study. Hughes et al. (2006) examined referral 
rates in 6-month intervals. Similar to US studies in FMS (Greenberg et al., 2003; 
Robinson et al., 2003; Robinson et al., 2004; Wolfe et a., 1997; Wassem et al., 2003; 
Bombardier and Buchwald, 1996) this study was conducted for 12-month interval, which 
is a common timeframe for resource utilization studies. 
 
With respect to the pharmacologic management of patients with FMS, this study found 
that significantly more patients with FMS were prescribed pharmacotherapy from one of 
the 10 selected categories during the 12-month period after being diagnosed (after index 
date) with FMS (97.7%) than during the period prior to the diagnosis (93.3%) (P < 
0.001), suggesting that pharmacotherapy with one or more of the 10 selected 
pharmacotherapy categories is an accepted treatment approach given a diagnosis of FMS. 
Analysis also found that patients with FMS were prescribed more pharmacotherapies in 
multiple categories after being diagnosed with FMS than in the period before diagnosis. 
In the post–index period relative to the pre–index period, more patients used two or more 
pharmacotherapies concurrently (66.2% vs. 52.3%; P < 0.001) and three or more 
pharmacotherapies concurrently (33.9% vs. 25.5%; P < 0.001). These findings are 
consistent with the profile of FMS as a chronic condition characterized by a variety of 
symptoms, including widespread body pain and muscle tenderness, fatigue, headaches, 
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and sleep disturbances (Wolfe et al., 1990), with an unclear etiology (Russell et al., 
1992a, Russell et al., 1992b; Schwarz et al., 1999; Yunus et al., 1992). 
Of the 10 selected pharmacotherapy categories in this study, NSAIDs, systemic 
corticosteroids, and TCAs were the most commonly prescribed pharmacotherapies and 
the utilization rates were higher after the FMS diagnosis than in the 12-month prior 
period. Although Hughes et al. (2006) analyzed pharmacotherapy utilization for only 
three pharmacotherapy classes (TCAs, SSRIs, and NSAIDs), that study also found that 
prescriptions for these three pharmacotherapy classes were higher among patients with 
FMS than among control patients (Hughes et al., 2006). 
 
In this study (as in the study by Hughes et al. [2006]), these pharmacotherapies may have 
been prescribed to patients with FMS prior to or following a FMS diagnosis, and may 
have been related to comorbid conditions rather than FMS. Nevertheless, the high rates of 
NSAID and systemic corticosteroid prescribing in this study are noteworthy, given that 
evidence-based guidelines have indicated there is no evidence to support the efficacy of 
these pharmacotherapies (Goldenberg et al., 2004). In particular, systemic corticosteroids 
are associated with a variety of concerning adverse effects, including weight gain; fluid 
and electrolyte disturbances (such as hypertension and increased calcium excretion, 
creating a risk for osteoporosis); musculoskeletal effects (such as muscle weakness); 
dermatological effects (such as impaired wound healing); endocrine effects (such as 
manifestation of latent diabetes mellitus); cardiovascular effects (such as myocardial 
rupture following recent myocardial infarction); as well as gastrointestinal, neurological, 
and metabolic effects (electronic Medicines Compendium, 2007). 
 
Using UK-specific sources to derive cost estimates (Curtis et al., 2007; BNF, 2006; NHS, 
2007), this study found the annual cost for FMS patients was £377 (£288 for GP visits 
and £88 for pharmacotherapies) in the 12-month prior period and £465 (£347 for GP 
visits and £119 for pharmacotherapies) in the 12-month period after FMS diagnosis. 
Similarly, in a study conducted in the United States using administrative claims data, 
Robinson et al. (2003) found that the total annual cost for FMS claimants was nearly 
twice that for typical beneficiaries ($5,945 vs. $2,486; P < 0.0001). 
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Limitations of the Study 
 
This study used the General Practice Research Database (GPRD) that is managed by the 
Medicines and Healthcare product Regulatory Agency and contains data for 8.9 million 
patients, with approximately 3 million active patients and over 35 million patient-years of 
data from more than 350 practices in the UK. It is the world’s largest source of primary 
care data taken from a single country’s health care system and covers the full cross 
section of the UK population. The GPRD contains longitudinal data from real-life clinical 
practices, with information on diagnoses, comorbidities, prescribing (including off-label 
use), co-prescribing, health outcomes, and demographic and lifestyle factors.  
 
The results of this study should be interpreted in the context of the limitations of the 
study design. First, because the study is restricted to patients who had a FMS diagnosis 
recorded by the GP, some patients may have met the ACR diagnostic criteria but 
remained undiagnosed because they consulted the GP less frequently than those who 
were diagnosed; therefore, the results of this study may not be generalizeable to other 
populations. Second, the use of primary care data precludes the use of patient 
assessments; as a result, the analysis cannot examine quality of life, functioning, or any 
clinical outcomes. Clinical investigations were also not available including visits for 
muscle pain, stiffness, or tender points, which may be the most common symptoms on 
which the diagnosis was based, and possibly those most affected by the diagnosis. Third, 
this database study does not capture over the counter medication. Finally, the analyses 
focused exclusively on medical and pharmacy resource utilization associated with a 
diagnosis of FMS; therefore, it does not include any other potentially important costs, 
such as productivity costs, cost of other medical interventions (such as physiotherapy), 
national cost of illness and disability benefits.  
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CHAPTER SIX: CONCLUSION 
 
FMS is a chronic and often debilitating condition. Treatment of FMS requires a 
comprehensive approach, including pharmacotherapy, cognitive-behavioral therapy, and 
physical exercise (Goldenberg et al., 2004). No pharmacotherapy is currently licensed for 
the treatment of FMS in the UK; however, there are a range of pharmacotherapies that 
may be used off label to manage FMS. Tricyclic antidepressants (TCAs) (e.g., 
amitriptyline) and muscle relaxants (e.g., cyclobenzaprine) have strong evidence of 
efficacy. Centrally acting analgesics (e.g., tramadol), selective serotonin reuptake 
inhibitors (SSRIs) (e.g., fluoxetine), serotonin-norepinephrine reuptake inhibitors 
(SNRIs) (e.g., duloxetine), and anticonvulsants (e.g., pregabalin) have modest evidence 
of efficacy. Although systemic corticosteroids, nonsteroidal anti-inflammatory drugs 
(NSAIDs), benzodiazepines, and nonbenzodiazepine sleep medications have no evidence 
of efficacy (Goldenberg et al., 2004), they may be prescribed to treat the symptoms of 
FMS before and after patients receive a definitive diagnosis. 
 
Because many patients affected by FMS are of prime working age, the condition may 
place a substantial economic burden on both private and public health care systems. In a 
2006 UK study (Hughes et al., 2006), researchers analyzed data from the General 
Practice Research Database (GPRD) and found that health care utilization declined in the 
short term after diagnosis, suggesting that resolution to a formal diagnosis helps patients 
cope with some of their symptoms. However, in the long term, resource utilization was 
found to increase, reverting back to the levels observed before diagnosis.  
 
This study examined levels of resource utilization and corresponding costs associated 
with FMS among primary care patients in the UK, both in the 12 months prior to and 
following a FMS diagnosis. The study assessed medical resource utilization in terms of 
general practitioner (GP) visits, specialist referrals, and inpatient hospital referrals. 
Pharmacotherapy resource utilization was examined in 10 pharmacotherapy categories 
identified a priori as relevant to patients with FMS based on the literature; these included 
anticonvulsants, benzodiazepines, centrally acting analgesics, muscle relaxants, 
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nonbenzodiazepine sleep medications, NSAIDs, SNRIs, SSRIs, systemic corticosteroids, 
and TCAs (Goldenberg et al., 2004).  
 
This study’s finding indicated that patients with FMS have greater GP-specific medical 
resource utilization, as well as greater pharmacotherapy resource utilization, in the 12-
month following an FMS diagnosis than in the 12-month prior to an FMS diagnosis. This 
increased resource utilization is reflected in higher associated costs following an FMS 
diagnosis relative to prior to the diagnosis. Results of these analyses provided a 
comprehensive characterization of medical and pharmacotherapy treatment for FMS, as 
well as the costs associated with FMS among UK primary care patients. 
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